Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Receivables (2020 - 2026)

Maxcyte has reported Receivables over the past 6 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Receivables fell 25.18% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 25.18% year-over-year, with the annual reading at $3.5 million for FY2025, 25.18% down from the prior year.
  • Receivables was $3.5 million for Q4 2025 at Maxcyte, down from $8.3 million in the prior quarter.
  • Over five years, Receivables peaked at $11.2 million in Q4 2022 and troughed at $3.5 million in Q4 2025.
  • The 5-year median for Receivables is $6.0 million (2024), against an average of $6.6 million.
  • Year-over-year, Receivables crashed 48.3% in 2023 and then soared 82.15% in 2025.
  • A 5-year view of Receivables shows it stood at $6.9 million in 2021, then soared by 62.5% to $11.2 million in 2022, then crashed by 48.3% to $5.8 million in 2023, then decreased by 18.97% to $4.7 million in 2024, then decreased by 25.18% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Receivables are $3.5 million (Q4 2025), $8.3 million (Q3 2025), and $5.8 million (Q2 2025).